Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127095661 | 12709566 | 1 | I | 201602 | 20160822 | 20160902 | 20160902 | EXP | FR-AFSSAPS-CF20160368 | FR-APOTEX-2016AP011023 | APOTEX | 86.00 | YR | F | Y | 0.00000 | 20160902 | CN | GB | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127095661 | 12709566 | 1 | PS | PAXIL | PAROXETINE HYDROCHLORIDE | 1 | Oral | 1 DF, QD (LONG STANDING TREATMENT) | U | 20031 | 1 | DF | TABLET | QD | |||||
| 127095661 | 12709566 | 2 | SS | TAHOR | ATORVASTATIN CALCIUM | 1 | Oral | 20 MG, QD (LONG STANDING TREATMENT) | U | 0 | 20 | MG | QD | ||||||
| 127095661 | 12709566 | 3 | SS | LASILIX /00032601/ | FUROSEMIDE | 1 | Oral | 40 MG, QD ( LONG STANDING TREATMENT) | U | 0 | 40 | MG | QD | ||||||
| 127095661 | 12709566 | 4 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 10 MG, QD | 0 | 10 | MG | QD | |||||||
| 127095661 | 12709566 | 5 | SS | SPECIAFOLDINE | FOLIC ACID | 1 | Oral | 10 MG, WE (LONG STANDING TREATMENT) | 0 | 10 | MG | /wk | |||||||
| 127095661 | 12709566 | 6 | SS | METOJECT | METHOTREXATE SODIUM | 1 | Subcutaneous | 1 DF, WE | 0 | 1 | DF | /wk | |||||||
| 127095661 | 12709566 | 7 | SS | BISOPROLOL FUMARATE. | BISOPROLOL FUMARATE | 1 | Oral | 2.5 MG, QD | 0 | 2.5 | MG | QD | |||||||
| 127095661 | 12709566 | 8 | SS | PREVISCAN (FLUINDIONE) | FLUINDIONE | 1 | Oral | 0 | |||||||||||
| 127095661 | 12709566 | 9 | SS | KARDEGIC | ASPIRIN LYSINE | 1 | Oral | 75 MG, QD ( LONG STANDING TREATMENT) | U | 0 | 75 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127095661 | 12709566 | 1 | Product used for unknown indication |
| 127095661 | 12709566 | 2 | Dyslipidaemia |
| 127095661 | 12709566 | 3 | Cardiac failure |
| 127095661 | 12709566 | 4 | Product used for unknown indication |
| 127095661 | 12709566 | 5 | Product used for unknown indication |
| 127095661 | 12709566 | 6 | Rheumatoid arthritis |
| 127095661 | 12709566 | 7 | Cardiac failure |
| 127095661 | 12709566 | 8 | Atrial fibrillation |
| 127095661 | 12709566 | 9 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127095661 | 12709566 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127095661 | 12709566 | Lung disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127095661 | 12709566 | 6 | 201409 | 20160208 | 0 |